title: Is methylene diphosphonate bone scan necessary for initial staging of Ewing sarcoma if 18F-FDG PET/CT is performed?
abstract: OBJECTIVE
  The purpose of this study was to determine whether methylene diphosphonate (MDP) bone scans are necessary during initial staging in patients with Ewing sarcoma (ES) in whom (18)F-FDG PET/CT is performed.
  
  
  METHODS
  A retrospective review was performed of patients who underwent FDG PET/CT and MDP bone scan before treatment of newly diagnosed ES from January 2004 to November 2012. Studies were reviewed to document suspected primary and metastatic malignancy. Pathology and imaging follow-up were used to determine the presence or absence of disease at suspected sites.
  
  
  RESULTS
  Sixty patients were identified in whom FDG PET/CT and MDP bone scans were performed before treatment of newly diagnosed ES. Forty-four primary malignancies had a lytic CT appearance, three were sclerotic, and 13 involved only soft tissue. In 11 of 12 patients with osseous metastases, these were detected on PET/CT, with the one false-negative occurring in a sclerotic primary tumor; in nine of 12 patients with osseous metastases, these were detected on MDP bone scan, with the three false-negatives occurring in patients with lytic primary tumors. Only one of 13 patients with a soft-tissue primary malignancy had bone metastases on both bone scan and PET/CT. PET/CT also showed that eight patients had lung metastases and three patients had lymph node metastases, which were not evident on MDP bone scan.
  
  
  CONCLUSIONS
  When ES is lytic, MDP bone scan does not add to staging performed by FDG PET/CT; thus, MDP bone scanning may be omitted. However, when ES is sclerotic, MDP bone scan may detect osseous metastases not detected by FDG PET/CT.
authors.affiliation: 1 Department of Radiology, Memorial Sloan-Kettering Cancer Center, 430 E 67th St, New York, NY.
authors.forename: Gary A
authors.initials: GA
authors.lastname: Ulaner
authors.forename: Heather
authors.initials: H
authors.lastname: Magnan
authors.forename: John H
authors.initials: JH
authors.lastname: Healey
authors.forename: Wolfgang A
authors.initials: WA
authors.lastname: Weber
authors.forename: Paul A
authors.initials: PA
authors.lastname: Meyers
mesh_terms: D000293:Adolescent; D000328:Adult; D050071:Bone Density Conservation Agents; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D002648:Child; D004164:Diphosphonates; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D064847:Multimodal Imaging; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012512:Sarcoma, Ewing / Q000000981:diagnostic imaging* / Q000473:pathology; D014057:Tomography, X-Ray Computed
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C027474:methylene diphosphonate